Boosting the Secretion of GLP-2 and GLP-1 Intestinal Hormones by Nutrients

Nestlé

Status: Completed

Conditions: Healthy

Treatments: Dietary Supplement: Placebo; Dietary Supplement: meal intake

Study type: Interventional

Funder types: Industry

Identifiers

NCT01727583

12.10.MET

Details and patient eligibility

About

This pilot study is aimed at assessing the acute effect of several combinations of lipids differing in their fatty acid composition on glucagon-like-peptide (GLP)-2 and GLP-1 secretion in healthy subjects.

Full description

In this study, the investigators aim to investigate the effect of various lipid types on GLP-2 and GLP-1 secretion. This will allow to determine the importance of lipids in nutritional solutions. Moreover, this will allow us to assess whether existing clinical formulas can be improved in order to stimulate GLP-2 and accelerate intestinal recovery.

Enrollment: 18 patients

Sex: Male

Ages: 20 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• BMI : 19 - 24.9 kg.m-2
• Normal fasting glycemia
• Having obtained his informed consent.

Exclusion criteria

• Gastro-intestinal disease (ulcer), pancreatic disease, hepatic disease, metabolic diseases / disorders (diabetes, dyslipidemia), renal disease, cardiovascular disease (arterial hypertension), as determined by the medical screening visit and a blood analysis.
• Have had a gastrointestinal surgery (with the exception of appendices resection).
• Malabsorption disorders
• Lactose intolerance
• Significant weight loss during the past three months (more than 5% of initial weight)
• Have a regular consumption of medication
• Regular supplements (vitamins and minerals) intake during the previous month
• Have an alcohol intake: > 2 units a day
• Smoker (more than 2 cigarettes a day)
• Illicit substances intake, as stated on the medical screening questionnaire
• Allergy to any food or medication
• Anaemia defined by a number of erythrocytes or hemoglobin Hb or hematocrit Ht which are inferior to laboratory normal ranges
• Having given blood in the past three months or willing to give blood in the 3 months following the completion of the study
• Intense physical activity > 3 hours per week
• Currently participating or having participated in another clinical trial during the past month.
• Volunteer who cannot be expected to comply with the protocol, including consuming rapidly the study products, chronic medication intake

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

18 participants in 5 patient groups, including a placebo group

Lipid 1

Active Comparator group

Description:

Meal intake

Treatment:

Dietary Supplement: meal intake

Lipid-free

Placebo Comparator group

Description:

Maltodextrine + proteins

Treatment:

Dietary Supplement: Placebo

Lipid 2

Active Comparator group

Description:

Meal intake

Treatment:

Dietary Supplement: meal intake

Lipid 3

Active Comparator group

Description:

Meal intake

Treatment:

Dietary Supplement: meal intake

Lipid 4

Active Comparator group

Description:

meal intake

Treatment:

Dietary Supplement: meal intake